InvestorsHub Logo
Followers 19
Posts 2315
Boards Moderated 0
Alias Born 03/12/2013

Re: guardiangel post# 26384

Monday, 11/24/2014 10:47:34 AM

Monday, November 24, 2014 10:47:34 AM

Post# of 30046
http://www.bizjournals.com/phoenix/stories/2010/07/26/focus3.html

This is why we believe ProvistaDX along with GCDX will sell Onko-Sure in the USA under the Radient/AMGL Dx.Inc. umbrella and Videssa under the ProvistaDx umbrella at a later date starting after June 2, 2015......imo Wolfie


1. How many patent applications has your company filed overall, and how many were this year?

2. What has the application process been like for you, and what do you think of the time frame for a response?

3. What do you think of the latest U.S. Supreme Court ruling affecting the patent process, and how will it affect your competitive edge?



William Gartner
President and CEO, Provista Life Sciences LLC


APPLICATIONS: Counting foreign countries, we have filed 186 patents on five different technologies. That includes all of our foreign patents, and approximately 65 of those have been filed this year in the individual countries.

PROCESS: The application process is simple to us because we do so many and have a great bioscience patent attorney.

RULING: The new ruling will have no impact on us. The ACLU v. the U.S. Patent Office and Myriad Genetics will have a huge positive impact on our business if the Supreme Court rules that genes cannot be patented.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.